Literature DB >> 17032930

Risk of venous thromboembolism among hospitalized medically ill patients.

John Edelsberg1, May Hagiwara, Charu Taneja, Gerry Oster.   

Abstract

PURPOSE: The 90-day risk of venous thromboembolism (VTE) among medically ill patients admitted to a hospital was estimated and is discussed.
SUMMARY: Patients aged > or =40 years who were hospitalized between January 1, 1998, and June 30, 2002, for reasons other than traumatic injury, labor and delivery, mental disorder, or VTE and who did not undergo surgery were identified in a large U.S. healthcare claims database. Patients receiving anticoagulants in the 90-day period preceding hospital admission were excluded. We estimated the percentage of study subjects who developed clinical deep-vein thrombosis (DVT) or pulmonary embolism (PE) within 90 days of hospital admission using Kaplan-Meier methods. We also estimated hazard ratios (HRs) for potential risk factors for VTE using univariate and stepwise multivariate Cox proportional hazards regression models. Among 92,162 study subjects, 1468 (1.59%) developed clinical DVT or PE within 90 days of hospital admission; 18% of these events occurred postdischarge. In multivariate analyses, significant risk factors for clinical VTE included: 1) history of cancer (HR, 1.67; 95% confidence interval [CI], 1.45-1.93); 2) history of VTE within six months of index admission (HR, 6.14; 95% CI, 4.74-7.96); 3) operating room procedure within 30 days of index admission (HR, 1.81; 95% CI, 1.47-2.24); 4) peripheral artery disease during index admission (HR, 1.68; 95% CI, 1.28-2.21); and 5) heart failure during index admission (HR, 1.72; 95% CI, 1.52-1.95).
CONCLUSION: The risk of clinical VTE among medically ill patients admitted to a hospital, although less than that of patients undergoing major surgery, is not negligible. Patients with a history of recent VTE or surgery, those who are admitted to the intensive care unit, those with an admitting diagnosis of heart failure, and those with active cancer are at especially high risk of VTE and deserve increased consideration for prophylaxis.

Entities:  

Mesh:

Year:  2006        PMID: 17032930     DOI: 10.2146/ajhp060389

Source DB:  PubMed          Journal:  Am J Health Syst Pharm        ISSN: 1079-2082            Impact factor:   2.637


  15 in total

Review 1.  Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing.

Authors:  Charles E Mahan; Mario Pini; Alex C Spyropoulos
Journal:  Intern Emerg Med       Date:  2010-02-23       Impact factor: 3.397

2.  Learning to predict post-hospitalization VTE risk from EHR data.

Authors:  Emily Kawaler; Alexander Cobian; Peggy Peissig; Deanna Cross; Steve Yale; Mark Craven
Journal:  AMIA Annu Symp Proc       Date:  2012-11-03

3.  Side effects of compression stockings: a case report.

Authors:  Bernard F Robertson; Collette H Thomson; Haroon Siddiqui
Journal:  Br J Gen Pract       Date:  2014-06       Impact factor: 5.386

4.  Current state of medical thromboprophylaxis in Australia.

Authors:  Sophie E Noel; J Alasdair Millar
Journal:  Australas Med J       Date:  2014-02-28

Review 5.  AF and Venous Thromboembolism - Pathophysiology, Risk Assessment and CHADS-VASc score.

Authors:  Nasir Shariff; Abdul Aleem; Mukesh Singh; Yuan Z Li; Stacey J Smith
Journal:  J Atr Fibrillation       Date:  2012-10-06

6.  Physician alerts to prevent symptomatic venous thromboembolism in hospitalized patients.

Authors:  Gregory Piazza; Erin J Rosenbaum; William Pendergast; Joseph O Jacobson; Robert C Pendleton; Gordon D McLaren; C Gregory Elliott; Scott M Stevens; William F Patton; Ousama Dabbagh; Marilyn D Paterno; Elaine Catapane; Zhongzhen Li; Samuel Z Goldhaber
Journal:  Circulation       Date:  2009-04-13       Impact factor: 29.690

7.  Incidence of venous thromboembolism in a homebound population.

Authors:  Jamal Ahmed; Katherine Ornstein; Andrew Dunn; Peter Gliatto
Journal:  J Community Health       Date:  2013-06

8.  Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients.

Authors:  S Phani Veeranki; Zhimin Xiao; Andrée Levorsen; Meenal Sinha; Bimal R Shah
Journal:  Am J Cardiovasc Drugs       Date:  2020-12-14       Impact factor: 3.571

9.  Measures of risk and their relationship to the relative size of a high-risk group: application to medical thromboprophylaxis.

Authors:  J Alasdair Millar
Journal:  Clin Epidemiol       Date:  2012-10-31       Impact factor: 4.790

10.  Prophylaxis of venous thromboembolism in medical patients: too much or too little?

Authors:  Christian Fynbo Christiansen
Journal:  Clin Epidemiol       Date:  2012-11-15       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.